Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

blog.png
GLY-article-photo640.jpg

Co-invented more than 200 patents and published 40 scientific articles that referenced 5000 times, Guo-Liang Yu co-founded and was chairman and CEO of Epitomics Inc. for 10 years until their recent acquisition by Abcam for $170M. As the new Executive Chairman of Crown Bioscience, his passion is bringing a fresh and vibrant change to an already highly successful organization.

“I’ve always been driven by my scientific curiosity and a passion to translate scientific discoveries into real products that might one day become truly life-changing, improving the quality of life for mankind.” Following his graduation from Fudan University in 1984, he moved to the USA and obtained his Ph.D. in UC...

Read more

October 29, 2013

The cost of failure

sinking_piggy640.jpg

Everyone’s been trying it over the last 10 years or more, but what has been the true impact of significant changes in pharmaceutical research and development, and what could be the future for drug discovery?

With such rapid and seismic shifts being made in the way the Pharmaceutical Industry operate over the last few years, there was a hope for significant beneficial effects in research pipelines and success in the clinic. These desired benefits do not seem to have been as widely borne out as was originally hoped for.

Read more
C-640.jpg

Oncology, as with other areas of Drug Discovery, is a shifting landscape. As we come towards the end of 2013 we look forward to what some of the current trends and focus of Oncology may be in 2014.

As a starting point, we wanted to compare and contrast the informal feedback from our scientists and business development teams with thought leadership from research and development organisations around the world. What are people talking about and what are they publishing on? We analysed the last 3 years of publications and presentations at AACR’s annual meetings and the AACR/EORTC Molecular Targets and Cancer Therapeutics conferences to look for potential trends, and found some surprising...

Read more
stop.jpg

In Oncology, drug resistance can limit the clinical benefit of a targeted agent. Understanding the molecular mechanisms of resistance is a key factor in discovering potential follow on drugs, combination therapies and treatment regimens for patients to manage their disease. But how do you model the multiplicity of options before entering the clinic?

For many decades now, the most common type of anti-cancer treatment has been conventional chemotherapy. However their broad-based mechanisms (e.g. DNA alkylating agents) usually lead to severe systemic side effects. Today, molecular targeted therapies which block specific molecules involved in cancer growth or progression, represent an...

Read more